Literature DB >> 7595570

Tumor necrosis factor-alpha and basic fibroblast growth factor decrease glial fibrillary acidic protein and its encoding mRNA in astrocyte cultures and glioblastoma cells.

G M Murphy1, Y L Lee, X C Jia, A C Yu, A Majewska, Y Song, K Schmidt, L F Eng.   

Abstract

Tumor necrosis factor-alpha is a pluripotent cytokine that is reportedly mitogenic to astrocytes. We examined expression of the astrocyte intermediate filament component glial fibrillary acidic protein in astrocyte cultures and the U373 glioblastoma cell line after treatment with tumor necrosis factor-alpha. Treatment with tumor necrosis factor-alpha for 72 h resulted in a decrease in content of glial fibrillary acidic protein and its encoding mRNA. At the same time, tumor necrosis factor-alpha treatment increased the expression of the cytokine interleukin-6 by astrocytes. The decrease in glial fibrillary acidic protein expression was greater when cells were subconfluent than when they were confluent. Thymidine uptake studies demonstrated that U373 cells proliferated in response to tumor necrosis factor-alpha, but primary neonatal astrocytes did not. However, in both U373 cells and primary astrocytes tumor necrosis factor-alpha induced an increase in total cellular protein content. Treatment of astrocytes and U373 cells for 72 h with the mitogenic cytokine basic fibroblast growth factor also induced a decrease in glial fibrillary acidic protein content and an increase in total protein level, demonstrating that this effect is not specific for tumor necrosis factor-alpha. The decrease in content of glial fibrillary acidic protein detected after tumor necrosis factor-alpha treatment is most likely due to dilution by other proteins that are synthesized rapidly in response to cytokine stimulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7595570     DOI: 10.1046/j.1471-4159.1995.65062716.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer's disease.

Authors:  M M Edwards; S R Robinson
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

2.  Aluminum stimulates uptake of non-transferrin bound iron and transferrin bound iron in human glial cells.

Authors:  Yongbae Kim; Luisa Olivi; Jae Hoon Cheong; Alex Maertens; Joseph P Bressler
Journal:  Toxicol Appl Pharmacol       Date:  2007-02-09       Impact factor: 4.219

3.  Reactive astrocytosis from excitotoxic injury in hippocampal organ culture parallels that seen in vivo.

Authors:  P E Kunkler; R P Kraig
Journal:  J Cereb Blood Flow Metab       Date:  1997-01       Impact factor: 6.200

4.  Prostaglandin E2 released from activated microglia enhances astrocyte proliferation in vitro.

Authors:  Dan Zhang; Xiaoming Hu; Li Qian; Belinda Wilson; Christopher Lee; Patrick Flood; Robert Langenbach; Jau-Shyong Hong
Journal:  Toxicol Appl Pharmacol       Date:  2009-05-03       Impact factor: 4.219

Review 5.  Inflammation in EAE: role of chemokine/cytokine expression by resident and infiltrating cells.

Authors:  L F Eng; R S Ghirnikar; Y L Lee
Journal:  Neurochem Res       Date:  1996-04       Impact factor: 3.996

6.  Intrathecal Resiniferatoxin Modulates TRPV1 in DRG Neurons and Reduces TNF-Induced Pain-Related Behavior.

Authors:  M Leo; M Schulte; L-I Schmitt; M Schäfers; C Kleinschnitz; T Hagenacker
Journal:  Mediators Inflamm       Date:  2017-08-02       Impact factor: 4.711

7.  Impact of Hepatoma-Derived Growth Factor Blockade on Resiniferatoxin-Induced Neuropathy.

Authors:  Chieh-Hsin Wu; Ming-Kung Wu; Chun-Ching Lu; Hung-Pei Tsai; Ying-Yi Lu; Chih-Lung Lin
Journal:  Neural Plast       Date:  2021-02-27       Impact factor: 3.599

8.  Aberrant signaling pathways in glioma.

Authors:  Mitsutoshi Nakada; Daisuke Kita; Takuya Watanabe; Yutaka Hayashi; Lei Teng; Ilya V Pyko; Jun-Ichiro Hamada
Journal:  Cancers (Basel)       Date:  2011-08-10       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.